uniQure (NASDAQ:QURE) received FDA fast track designation for AMT-130, a gene therapy candidate for the treatment of Huntington’s disease (HD). HD is an inherited neurodegenerative disorder where production and...
PhaseBio Pharmaceuticals (NASDAQ:PHAS) received the FDA’s breakthrough therapy designation for PB2452, a drug designed to reverse the effects of antiplatelet drug, ticagrelor. Ticagrelor is administered to patients to...
Provention Bio (NASDAQ:PRVB) has dosed the first patient in its Phase 3 clinical trial of teplizumab for Type 1 diabetes (T1D). The trial will determine whether teplizumab, an anti-CD3 monoclonal antibody, slows the...
Chembio Diagnostics’ (NASDAQ:CEMI) Zika/dengue/chikungunya multiplex test has been approved by Brazil’s health regulatory agency, ANVISA. The test uses Chembio’s DPP technology platform to detect both active infection...
Valeritas Holdings’ (NASDAQ:VLRX) V-Go wearable insulin delivery device significantly lowered Type 2 diabetes (T2D) patients’ average A1C levels, compared with those using standard insulin treatment. Valeritas’ V-GoAL...
Trovagene (NASDAQ:TROV) announced positive interim data from its Phase 1b/2 dose escalation trial of onvansertib, in combination with standard-of-care chemotherapy, in acute myeloid leukemia (AML) patients. Three of six...
SELLAS Life Sciences Group (NASDAQ:SLS) and Memorial Sloan Kettering Cancer Center will conduct a Phase 1 study of SELLAS’ galinpepimut-S (GPS) in combination with nivolumab in patients with relapsed or refractory...
Homology Medicines (NASDAQ:FIXX) received FDA clearance to commence its Phase 1/2 study of HMI-102 in adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU lack the...
Entasis Therapeutics (NASDAQ:ETTX) has initiated a Phase 3 pivotal clinical trial to evaluate ETX2514 and sulbactam (ETX2514SUL) for the treatment of carbapenem-resistant A. baumannii infections. A. baumannii causes...
Profound Medical (TSX:PRN; OTCQX:PRFMF) reported positive top line results from the TACT pivotal study designed to support its application to the FDA for 510(k) clearance to market TULSA-PRO in the U.S. The TULSA-PRO...
BriaCell Therapeutics (TSX-V:BCT) (OTCQB:BCTXF) announced that early Phase 1/2a data suggest its Bria-IMT immunotherapy, combined with the checkpoint inhibitor KEYTRUDA, demonstrated additive or synergistic anti-tumor...
Evogene (NASDAQ, TASE:EVGN) has established a new subsidiary, Canonic, to develop next generation medical cannabis products. Evogene has been evaluating the medical cannabis field for more than a year, including market...
BDO USA acquired BioProcess Technology Consultants, a provider of chemistry, manufacturing and controls (CMC) consulting services to the global biopharmaceutical industry. The acquisition of BioProcess bolsters BDO’s...
Ziopharm Oncology’s (NASDAQ:ZIOP) controlled IL-12 program received FDA fast track designation for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. Controlled IL-12 consists of IL-12...
Idera Pharma (NASDAQ:IDRA) presented results of its Phase 1 trial of tilsotolimod as monotherapy in patients with various refractory solid tumors. Tilsotolimod is a toll-like receptor 9 agonist that activates cancer...
ADMA Biologics’ (NASDAQ:ADMA) ASCENIV has received FDA approval for the treatment of primary humoral immunodeficiency disease (PI) in adults and adolescents. The approval is based on results of a pivotal Phase 3...
Advaxis’ (NASDAQ:ADXS) ADSX-NEO has demonstrated significant anti-tumor activity in a Phase 1 study of patients with certain types of advanced or metastatic solid tumors. ADXS-NEO is a live, attenuated Listeria...
Closely-held Ocutrx Vision Technologies announced issuance of the company’s second U.S. patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart: DPD2) has completed assembly of its i/Blue Imaging System’s functional unit, which has met the company’s pre-established performance expectations. The...
Aphria (TSX:APHA; NYSE:APHA) has launched CannRelief, a cannabidiol (CBD)-based nutraceutical and cosmetics line, through its subsidiary Aphria Deutschland. Featuring hemp-derived CBD, CannRelief products are produced...
Closely-held Blume, a young women’s self help and periods products company, raised $3.3-million in a seed funding round, led by Grace Chou and Victoria Treyger, partners at Felicis Ventures, with participation from...
The European Medicine Agency’s (EMA) advisory committee (CHMP) affirmed that a 1gm daily dose of omega-3s are not effective in preventing further cardiovascular (CV) problems in patients who have had a heart attack. The...